fbpx

Search Our Clinical Trials

Conducting trials on a wide range of cancer treatments

The Oncology Institute of Hope and Innovation is a leader in clinical studies, with the goal to advance the treatment of cancer. We conduct more trials than most other community cancer groups in the US. Our research helps us evaluate the effectiveness of treatment, reduce the risk of complications, lower costs and save resources, and continually refine our clinical approach to cancer care.

Lymphoma

NCT04384484

Ph 3 Study of Loncastuximab Tesirine Combined with Rituximab Versus Immunochemotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-5)

Request Information
Breast

NCT04829604

Ph 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer that is is Resistant or Refractory to T-DM1, and/or T-DXd, and/or Tucatinib-containing Regimens.

Request Information

D8535C00001

Ph 3 Study of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in ER+/HER2- Early Breast Cancer and an Intermediate-High Risk of Recurrence with Completed Definitive Locoregional Therapy and 2+ years of Standard Adjuvant Endocrine-Based Therapy without Disease Recurrence (CAMBRIA-1 / NSABP B-62)

Request Information

NCT05629585

Ph 3 Study of Datopotamab Deruxtecan (Dato-DXd) with or without Durvalumab versus Investigator’s Choice of Therapy in Stage I-III Triple-negative Breast Cancer with Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03)

Request Information

NCT05747794

Ph 3 Study of Eftilagimod Alpha (soluble LAG-3) in HER2-Neg/Low Metastatic Breast Cancer Receiving Paclitaxel

Request Information

NCT05593094

Ph 1 Study of ZN-A-1041 (HER-2 Inhibitor) Enteric Capsules as a Single Agent or in Combination in HER2-Positive Advanced Solid Tumors

Request Information
Gastric

NCT05111626

Ph 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer with FGFR2b Overexpression (FORTITUDE-102)

Request Information
Non-Small Cell Lung Cancer

NCT05687266

Ph 3 Study of Datopotamab Deruxtecan (Dato-DXd) plus Durvalumab and Carboplatin Versus Pembrolizumab plus Platinum-based Chemotherapy for the First-line Treatment of Locally Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (AVANZAR)

Request Information

NCT05502237

Ph 3 Study of Zimberelimab and Domvanalimab plus Chemotherapy Versus Pembrolizumab plus Chemotherapy for 1L Treatment of Metastatic NSCLC With No EGFR or ALK Genomic Tumor Aberrations

Request Information

NCT05609578

Ph 2 Study of Combination Therapies with Adagrasib in Advanced NSCLC with KRAS G12C Mutation

Request Information

NCT05671510

Ph 3 Study of ONC-392 (Anti-CTLA-4 mAb) Versus Docetaxel in Metastatic NSCLC that Progressed on PD-1/PD-L1 Inhibitors

Request Information

NCT05557591

Ph 1/2 Study of Cemiplimab (Anti-PD-1 Antibody) + BNT116 (Fixvac Lung) Versus Cemiplimab Alone in First-Line Treatment of Advanced NSCLC expressing PD-L1 >50%

Request Information

NCT06267001

Ph 3 Study of Tiragolumab plus Atezolizumab versus Placebo plus Atezolizumab in completely resected Stage IIB, IIIA, or Select IIIB, PD-L1 positive NSCLC who have received adjuvant platinum-based chemo

Request Information

NCT05184712

"A Randomized, Double-blind, Multi-center, Phase III Study of AK112 or Placebo Combined with Pemetrexed Carboplatin in Patients with EGFR-mutant Locally Advanced or Metastatic Non-squamous NSCLC Who Have Failed to EGFR-TKI Treatment (HARMONi)"

Request Information
Colorectal

NCT05609370

Ph 1b/2 Study LBL-007 (anti-LAG-3) plus Tislelizumab in Combination with Bevacizumab plus Fluoropyrimidine Versus Bevacizumab plus Fluoropyrimidine as Maintenance Therapy in Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer

Request Information

NCT04759664

Ph 2 Study of Topically Administered LUT014 (Topical B-Raf Inhibitor) in Metastatic Colorectal Cancer Patients with EGFR Inhibitor Induced Acneiform Lesions.

Request Information
Multiple Myeloma

NCT05552976

Ph 3 Study of CC-92480 (BMS-986348), Carfilzomib, and Dexamethasone (480Kd) Versus Carfilzomib and Dexamethasone (Kd) in Relapsed or Refractory Multiple Myeloma (RRMM)

Request Information

NCT05028348

Ph 3 Study of Selinexor, Pomalidomide and Dexamethasone (SPd) versus Elotuzumab, Pomalidomide and Dexamethasone (EloPd) in Relapsed or Refractory Multiple Myeloma (RRMM)

Request Information
Advanced Solid Tumors

NCT05150691

Ph 1/2a Study of DB-1303 in Advanced/ Metastatic Solid Tumors

Request Information

NCT04140526

Ph 1a/1b Study of ONC-392 (Anti-CTLA-4 mAb) Alone and in Combination with Pembrolizumab in Advanced Solid Tumors (Melanoma and NSCLC)

Request Information
Diagnostic Test

NCT05059444

ORACLE: Observation of ResiduAl Cancer with Liquid biopsy Evaluation

Request Information
Leukemia

NCT05963074

Ph 2 Study of Customized Ibrutinib Treatment Regimens for Chronic Lymphocytic Leukemia (TAILOR)

Request Information

NCT05384587

Ph 2 Study of Asciminib (BCR::ABL1 kinase inhibitor) monotherapy in 2nd and 1st Line Chronic Phase- Chronic Myelogenous Leukemia (ASC2ESCALATE)

Request Information
Urothelial malignancy

NCT04879329

Ph 3 study of Disitamab vedotin plus Pembrolizumab versus Chemotherapy in Previously untreated locally advanced or metastatic HER2+ Urothelial Carcinoma (IHC 1+ and greater)

Request Information
Prostate

NCT04986423

Ph 2b Study of ZEN003694 with Enzalutamide versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer

Request Information
Skip to content